Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL202 in Advanced Solid Tumors
NCT07202364Phase 2Recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Aug 2025
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of YL202 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), Cervical Cancer (CC), solid tumor, sponsored by MediLink Therapeutics. Started Aug 2025; status: recruiting.
02
Drugs
YL202
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)Cervical Cancer (CC)solid tumor
Beyond the preview
Go deeper on NCT07202364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07202364.